{"hands_on_practices": [{"introduction": "A core task in systems biology is to build mechanistic bridges between different layers of biological information. This exercise guides you through a foundational practice: connecting an observed change in gene expression to a specific change in metabolite levels using established pathway knowledge. By working through this hypothetical scenario, you'll practice the deductive reasoning required to form a testable hypothesis linking a genetic event to its metabolic consequence [@problem_id:1440042].", "problem": "A systems biology research group is investigating the metabolic response of liver cells to prolonged fasting. They compare data from normal fasting cells (control) with cells carrying a specific genetic variant (experimental). Their analysis yields two key datasets:\n\n1.  **Transcriptomic Data**: A list of genes that are differentially expressed. The only gene found to be significantly upregulated in the experimental cells compared to the control is *PCK1*. The expression levels of other metabolic genes, such as *PFKL* (encoding the liver-type phosphofructokinase) and *HK2* (encoding hexokinase 2), are not significantly changed.\n\n2.  **Metabolomic Data**: A list of metabolites with altered concentrations. The only metabolite found at a significantly increased concentration in the experimental cells is Phosphoenolpyruvate (PEP). The levels of glucose and pyruvate are not significantly different between the two conditions.\n\nTo connect these observations, the team consults a simplified pathway database, which contains the following established biochemical relationships:\n\n*   **Rule 1**: The gene *PCK1* encodes the enzyme Phosphoenolpyruvate Carboxykinase 1.\n*   **Rule 2**: The enzyme Phosphoenolpyruvate Carboxykinase 1 catalyzes the conversion of oxaloacetate into Phosphoenolpyruvate.\n*   **Rule 3**: The enzyme liver-type phosphofructokinase (encoded by *PFKL*) catalyzes the conversion of fructose-6-phosphate into fructose-1,6-bisphosphate.\n*   **Rule 4**: The enzyme pyruvate kinase catalyzes the conversion of Phosphoenolpyruvate into pyruvate.\n*   **Rule 5**: The enzyme hexokinase 2 (encoded by *HK2*) catalyzes the conversion of glucose into glucose-6-phosphate.\n\nBased *only* on the information provided, which of the following statements presents the most direct and plausible mechanistic hypothesis linking the observed genetic change to the observed metabolic change?\n\nA. The upregulation of *PCK1* leads to an increased concentration of pyruvate because its product, PEP, is the substrate for pyruvate synthesis.\n\nB. The upregulation of *PCK1* leads to an increased rate of synthesis of Phosphoenolpyruvate from oxaloacetate.\n\nC. The increased concentration of Phosphoenolpyruvate is caused by the unchanged expression of the *PFKL* gene.\n\nD. The accumulation of Phosphoenolpyruvate is a result of decreased activity of pyruvate kinase, creating a bottleneck.\n\nE. The expression of the *HK2* gene is stable, causing the accumulation of Phosphoenolpyruvate upstream in the metabolic network.", "solution": "We are given two observations and five pathway rules. The transcriptomic observation is that only the gene *PCK1* is upregulated in experimental cells; other genes cited (*PFKL*, *HK2*) have unchanged expression. By Rule 1, *PCK1* encodes Phosphoenolpyruvate Carboxykinase 1 (PEPCK1). By Rule 2, PEPCK1 catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP). Therefore, upregulation of *PCK1* implies an increased concentration of the enzyme PEPCK1, which increases the catalytic capacity for the reaction OAA $\\to$ PEP.\n\nFrom enzyme kinetics, increasing the total enzyme concentration increases the maximum catalytic rate according to\n$$\nV_{\\max} = k_{\\text{cat}}[E]_{\\text{total}},\n$$\nand for a Michaelis–Menten mechanism, the reaction rate for PEP production satisfies\n$$\nv_{\\text{PEP production}} = \\frac{V_{\\max}[{\\text{OAA}}]}{K_{m} + [{\\text{OAA}}]}.\n$$\nThus, an increase in $[E]_{\\text{total}}$ (PEPCK1) increases $V_{\\max}$ and thereby increases $v_{\\text{PEP production}}$ for any fixed $[{\\text{OAA}}]$, leading to a higher rate of synthesis of PEP from OAA.\n\nThe metabolomic observation is that only PEP is significantly increased; glucose and pyruvate are unchanged. This pattern is directly consistent with an increased production of PEP at its synthesis step (OAA $\\to$ PEP), without requiring changes in upstream glycolytic entry (HK2; Rule 5) or the PFKL-catalyzed step (Rule 3), both of which are reported unchanged at the expression level, and without needing to invoke changes in pyruvate kinase (Rule 4), for which no evidence is provided and which would be expected to alter pyruvate if it were the primary bottleneck.\n\nEvaluate the options:\n- Option B states that upregulation of *PCK1* leads to an increased rate of synthesis of PEP from OAA. This follows directly from Rules 1–2 and the kinetic relation $V_{\\max} = k_{\\text{cat}}[E]_{\\text{total}}$, matching the observed increase in PEP.\n- Option A predicts an increased concentration of pyruvate because PEP is a substrate for pyruvate synthesis (Rule 4), but the data show pyruvate is unchanged; moreover, this is less direct than the immediate product of PEPCK1.\n- Option C attributes increased PEP to unchanged *PFKL* expression, but Rule 3 concerns fructose-6-phosphate to fructose-1,6-bisphosphate and provides no direct mechanistic link to PEP; unchanged expression cannot explain a differential increase in PEP.\n- Option D posits decreased pyruvate kinase activity causing a bottleneck at PEP, but there is no evidence provided about pyruvate kinase, and a strong bottleneck would be expected to reduce pyruvate, which is reported unchanged.\n- Option E attributes PEP accumulation to stable *HK2* expression, but Rule 5 concerns glucose to glucose-6-phosphate; unchanged HK2 is not a plausible cause of increased PEP given no changes are observed in glucose and the step is far upstream of PEP in this simplified network.\n\nTherefore, the most direct and plausible mechanistic hypothesis, using only the provided information, is that upregulation of *PCK1* increases the rate of PEP synthesis from OAA.", "answer": "$$\\boxed{B}$$", "id": "1440042"}, {"introduction": "While the central dogma provides a blueprint, the correlation between messenger RNA ($mRNA$) abundance and protein abundance is often imperfect due to post-transcriptional and post-translational regulation. This practice introduces a classic method for visualizing the relationship between the transcriptome and the proteome on a global scale [@problem_id:1440088]. Interpreting the resulting four-quadrant plot is a key skill for identifying a gene's dominant mode of regulation, from simple transcriptional control to more complex dynamics like protein degradation.", "problem": "In a systems biology experiment, researchers are investigating how yeast cells adapt to a sudden heat shock. They grow a culture of yeast at an optimal temperature and then shift it to a much higher, stressful temperature. After one hour, they collect the cells and perform a genome-wide analysis of both the transcriptome and the proteome. For each gene, they calculate the log2 fold-change (log2FC) of its messenger RNA (mRNA) abundance and its corresponding protein abundance, comparing the heat-shocked cells to the control cells at the optimal temperature.\n\nThe data is visualized on a scatter plot where the x-axis represents the mRNA log2FC and the y-axis represents the protein log2FC. The plot is divided into four quadrants:\n- **Quadrant I**: mRNA log2FC > 0 and Protein log2FC > 0\n- **Quadrant II**: mRNA log2FC < 0 and Protein log2FC > 0\n- **Quadrant III**: mRNA log2FC < 0 and Protein log2FC < 0\n- **Quadrant IV**: mRNA log2FC > 0 and Protein log2FC < 0\n\nBelow is a list of potential dominant biological interpretations for the genes found in these quadrants.\n\n**Interpretations:**\n*   **A.** The primary regulatory control is transcriptional down-regulation, leading to a corresponding decrease in protein synthesis.\n*   **B.** Transcriptional activity is increasing, but this is counteracted by mechanisms such as increased protein degradation or translational repression, leading to a net decrease in protein levels.\n*   **C.** The primary regulatory control is transcriptional up-regulation, resulting in a corresponding increase in protein synthesis.\n*   **D.** Transcriptional activity is decreasing, but post-translational or post-transcriptional mechanisms, such as decreased protein degradation or enhanced translational efficiency, lead to a net increase in protein levels.\n\nWhich of the following options correctly matches each quadrant with its most likely dominant biological interpretation?\n\nA. I-A, II-B, III-C, IV-D\n\nB. I-C, II-D, III-A, IV-B\n\nC. I-C, II-A, III-D, IV-B\n\nD. I-A, II-D, III-C, IV-B\n\nE. I-B, II-C, III-A, IV-D", "solution": "Let $x$ denote the mRNA $\\log_{2}\\mathrm{FC}$ (x-axis) and let $y$ denote the protein $\\log_{2}\\mathrm{FC}$ (y-axis). By definition of the quadrants:\n- Quadrant I: $x>0$ and $y>0$.\n- Quadrant II: $x<0$ and $y>0$.\n- Quadrant III: $x<0$ and $y<0$.\n- Quadrant IV: $x>0$ and $y<0$.\n\nInterpret each quadrant using the stated biological controls:\n1) For Quadrant I ($x>0$, $y>0$), both mRNA and protein increase. A natural dominant mechanism is transcriptional up-regulation that propagates to protein, matching interpretation C.\n\n2) For Quadrant II ($x<0$, $y>0$), mRNA decreases while protein increases. This implies compensatory post-transcriptional or post-translational regulation (e.g., enhanced translation or reduced protein degradation) that overrides the transcriptional decrease, matching interpretation D.\n\n3) For Quadrant III ($x<0$, $y<0$), both mRNA and protein decrease. A natural dominant mechanism is transcriptional down-regulation that propagates to protein, matching interpretation A.\n\n4) For Quadrant IV ($x>0$, $y<0$), mRNA increases while protein decreases. This implies that translational repression or increased protein degradation counteracts the transcriptional increase, matching interpretation B.\n\nTherefore, the correct mapping is I-C, II-D, III-A, IV-B, which corresponds to option B.", "answer": "$$\\boxed{B}$$", "id": "1440088"}, {"introduction": "To dissect the layers of gene regulation, we often need to move beyond qualitative insights and perform quantitative analyses. This hands-on problem demonstrates how to integrate two powerful sequencing techniques—RNA-seq for transcript abundance and Ribo-seq for active translation—to calculate a crucial metric known as Translational Efficiency ($TE$) [@problem_id:1440072]. By calculating the change in $TE$ for a gene of interest, you will learn how to isolate and quantify the effects of a perturbation specifically on the process of protein synthesis.", "problem": "A team of systems biologists is investigating the cellular response to a new drug candidate in a human cancer cell line. They aim to understand how the drug affects protein synthesis, distinguishing between changes in gene transcription and changes in translation. To do this, they perform two parallel high-throughput sequencing experiments on cell cultures before (control) and after (treated) a 24-hour drug exposure: Ribosome profiling (Ribo-seq), which measures the abundance of ribosome-protected messenger RNA (mRNA) fragments, and RNA sequencing (RNA-seq), which measures the abundance of total mRNA transcripts. The abundance for each gene is quantified in Reads Per Kilobase of transcript per Million mapped reads (RPKM).\n\nThe Translational Efficiency (TE) for a given gene is defined as the ratio of its abundance in the Ribo-seq dataset to its abundance in the RNA-seq dataset. A higher TE indicates that a greater proportion of the available mRNA transcripts for that gene are being actively translated into protein.\n\nThe team has collected the following data for a specific gene of interest, *GSK3B*:\n- **Control Condition (before drug):**\n  - RNA-seq abundance: 145.2 RPKM\n  - Ribo-seq abundance: 440.0 RPKM\n- **Treated Condition (after drug):**\n  - RNA-seq abundance: 98.5 RPKM\n  - Ribo-seq abundance: 760.0 RPKM\n\nTo quantify the change in translational control for *GSK3B* after drug treatment, calculate the log2 fold change of its translational efficiency. Round your final answer to three significant figures.", "solution": "Translational efficiency for a gene is defined as the ratio of its abundance in Ribo-seq to its abundance in RNA-seq:\n$$\n\\mathrm{TE}=\\frac{\\text{Ribo-seq}}{\\text{RNA-seq}}.\n$$\nFor the control condition:\n$$\n\\mathrm{TE}_{\\mathrm{ctrl}}=\\frac{440.0}{145.2}=\\frac{4400}{1452}=\\frac{1100}{363}\\approx 3.030303\\ldots.\n$$\nFor the treated condition:\n$$\n\\mathrm{TE}_{\\mathrm{treat}}=\\frac{760.0}{98.5}=\\frac{760}{197/2}=\\frac{1520}{197}\\approx 7.715228\\ldots.\n$$\nThe fold change in translational efficiency is the ratio\n$$\n\\mathrm{FC}_{\\mathrm{TE}}=\\frac{\\mathrm{TE}_{\\mathrm{treat}}}{\\mathrm{TE}_{\\mathrm{ctrl}}}\n=\\frac{\\frac{760.0}{98.5}}{\\frac{440.0}{145.2}}\n=\\frac{760.0\\times 145.2}{98.5\\times 440.0}\n=\\frac{2508}{985}\\approx 2.5461928934.\n$$\nThe log base 2 fold change is\n$$\n\\log_{2}\\!\\left(\\mathrm{FC}_{\\mathrm{TE}}\\right)=\\log_{2}\\!\\left(\\frac{2508}{985}\\right)\n=\\frac{\\ln\\!\\left(\\frac{2508}{985}\\right)}{\\ln 2}\\approx 1.348356\\ldots.\n$$\nRounding to three significant figures gives\n$$\n1.35.\n$$", "answer": "$$\\boxed{1.35}$$", "id": "1440072"}]}